Oct. 14, 2026
MURR announces availability of Terbium-161
October 14, 2026Contact: Shayne Martin, shayne.martin@missouri.edu The University of Missouri Research Reactor (MURR) will provide Terbium-161 (Tb-161) to the global marketplace in support of emerging cancer research by the end of the year. Beginning in December of 2026, MURR will support monthly batches of radiochemical grade Tb-161, with plans to scale and transition to weekly batches produced under good manufacturing practices (GMP) by the end of 2027. Tb-161 is a chemical cousin to lutetium-177 (Lu-177), also produced at MURR, which is currently used in two FDA-approved cancer treatments. Like Lu-177, Tb-161 targets cancer cells with…
Oct. 14, 2026
Sixty years later, Missouri’s bold investment in nuclear science continues to save and improve lives
Mizzou is harnessing the power of MURR and NextGen MURR to fight cancer, strengthen U.S. supply chains, support national defense and drive breakthroughs in health, energy and technology.
Oct. 4, 2026
MURR and Curium extend partnership to strengthen supply of critical cancer-fighting radioisotope
Lutetium-177 — a radioisotope produced at the University of Missouri — is used in precision therapies that target and destroy cancer cells.
May 13, 2026
Mizzou breaks ground on Radioisotope Science Center to strengthen nation’s supply of critical isotopes
University of Missouri leaders, federal partners and state officials celebrated the groundbreaking of the new Radioisotope Science Center (RSC) at Discovery Ridge Research Park, marking a major milestone in strengthening the nation’s supply of critical radioisotopes for medicine, research and national security.
March 30, 2026
ABK Biomedical and MURR forge long-term partnership to advance breakthrough cancer therapy
A new agreement names MURR as the primary irradiation partner for ABK Biomedical's Eye90 microspheres.
March 23, 2026
DOE and MURR secure critical radioisotope supply chain for medical imaging
The University of Missouri Research Reactor is now the only domestic supplier of gadolinium-153 through a new agreement with the Department of Energy.
March 17, 2026
NextGen MURR teams with Burns & McDonnell, supporting the future of lifesaving nuclear medical isotope production
The drive to build a new state-of-the-art research reactor at Mizzou continues as a major milestone is reached.
March 8, 2026
MURR makes NCA Lu-177 available worldwide
Expanded supply will enable researchers and industry to purchase GMP no-carrier-added Lutetium-177 directly from the reactor.
Feb. 8, 2026
University of Missouri conducts first in-person clinical trial for nuclear medicine breakthrough device
The clinical trial marks the latest human trial at Mizzou involving radioisotopes to treat cancer.
Jan. 25, 2026
Investigating sickle cell disease with SNMMI grant
A new imaging agent may reveal the causes of pain in sickle cell disease.